摘要
1例64岁男性患者因肺部感染给予莫西沙星0.4 g,1次/d静脉滴注,并口服肺力咳胶囊及西替利嗪。第2天,血生化检查示丙氨酸转氨酶(ALT)49 U/L、天冬氨酸转氨酶(AST)30 U/L。第5天ALT及AST分别升至166 U/L、53 U/L。第9天停用莫西沙星,改为左氧氟沙星0.5 g,1次/d口服,并行保肝治疗,肺力咳胶囊及西替利嗪按原剂量继续服用。第10天ALT 111 U/L,AST28 U/L;第13天ALT 77 U/L,AST 23 U/L。2个月后肝功能恢复正常(ALT 28 U/L,AST21 U/L)。
A 64-year-old man received an IV infusion of moxifloxacin 0. 4 g once daily with concomitant use of oral Feilike capsules （肺力咳胶囊）and oral cetirizine for pulmonary infection. On day 2, biochemical tests showed an alanine aminotransferase （ALT） level of 49 U/L and an aspartate aminotransferase （AST） level of 30 U/L. On day 5, the values of ALT and AST rose to 166 U/L and 53 U/L, respectively. On day 9, moxifloxacin was withdrawn and changed to levofloxacin 0.5 g once daily orally. Meanwhile, liver-protective treatment was given and Feilike capsules and cetirizine were continued at original dosage. On day 10, the values of ALT and AST were respectively 111 U/L and 28 U/L, and on day 13, the value of ALT was 77 U/L and the value of AST was 23 U/L. Two months later, hepatic function returned to normal （ an ALT level of 28 U/L and an AST level of 21 U/L）.
出处
《药物不良反应杂志》
CSCD
2013年第2期105-106,共2页
Adverse Drug Reactions Journal
关键词
莫西沙星
药物性肝损害
Moxifloxacin
Drug-induced liver injury
